首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV
【2h】

Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV

机译:包含乳化亚微米颗粒和H5N1 / EV71 / JEV灭活病毒颗粒的三价疫苗的配制和免疫学评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Combination vaccines can reduce the number of injections and simplify the immunization schedule required to prevent different diseases. Here we assessed the immunogenicity in a mouse model of a vaccine composition comprising inactivated influenza viruses (H5N1/H1N1), enterovirus 71 (EV71), and/or Japanese encephalitis virus (JEV) and investigated whether the vaccine formulations can overcome the immunologic interference between the individual vaccine components. We demonstrated that the antigenic competition happens between H5N1/H1N1 or H5N1/EV71 inactivated virions when the vaccine combinations either formulated with Alum suspensions or without adjuvant. In the presence of PELC emulsified particles, EV71-specific immune responses before and after incorporating H5N1 virus into EV71 vaccine were detected of no significant difference; in addition, H5N1- and EV71-specific immune responses were found at the same level when H5N1/EV71/JEV consolidating into combination vaccine. Emulsified vaccine formulation was represented as a potential tool that is found to reduce the number of injections required to prevent multiple infectious strains causing the same disease (H5N1/H1N1) and/or that protect against different diseases (H5N1/EV71). Combination vaccines can also include a third component to protect against H5N1/EV71/JEV at the same time.
机译:组合疫苗可以减少注射次数并简化预防不同疾病所需的免疫程序。在这里,我们评估了包含灭活流感病毒(H5N1 / H1N1),肠病毒71(EV71)和/或日本脑炎病毒(JEV)的疫苗组合物在小鼠模型中的免疫原性,并研究了疫苗制剂是否可以克服两者之间的免疫干扰各个疫苗成分。我们证明了当使用明矾悬浮液或不使用佐剂配制疫苗组合时,抗原竞争发生在H5N1 / H1N1或H5N1 / EV71灭活病毒颗粒之间。在存在PELC乳化颗粒的情况下,检测到将H5N1病毒掺入EV71疫苗之前和之后,EV71特异性免疫反应均无显着差异。此外,当H5N1 / EV71 / JEV合并为联合疫苗时,发现H5N1-和EV71特异性免疫反应处于相同水平。乳化疫苗制剂被认为是一种潜在的工具,可以减少预防引起同一疾病(H5N1 / H1N1)的多种传染株和/或预防不同疾病(H5N1 / EV71)所需的注射次数。组合疫苗还可以包含第三种成分,以同时预防H5N1 / EV71 / JEV。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号